• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

会议报告:“下一代流感疫苗的保护相关因素:从 COVID-19 大流行中吸取的经验教训”。

Meeting Report From "Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID-19 Pandemic".

机构信息

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, New York, USA.

出版信息

Influenza Other Respir Viruses. 2024 Oct;18(10):e13314. doi: 10.1111/irv.13314.

DOI:10.1111/irv.13314
PMID:39380156
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11461279/
Abstract

BACKGROUND

This report summarizes the discussions and conclusions from the "Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned from the COVID-19 Pandemic" meeting, which took place in Seattle, USA, from March 1, 2023, to March 3, 2023.

CONCLUSIONS

Discussions around influenza virus correlates of protection and their use continued from where the discussion had been left off in 2019. While there was not much progress in the influenza field itself, many lessons learned during the coronavirus disease 2019 (COVID-19) pandemic, especially the importance of mucosal immunity, were discussed and can directly be applied to influenza correlates of protection.

摘要

背景

本报告总结了于 2023 年 3 月 1 日至 3 月 3 日在美国西雅图举行的“下一代流感疫苗保护相关因素:从 COVID-19 大流行中吸取的教训”会议的讨论和结论。

结论

会议继续讨论了流感病毒保护相关因素及其应用,这是在 2019 年讨论的基础上进行的。虽然流感领域本身没有取得太多进展,但在冠状病毒病 2019(COVID-19)大流行期间吸取了许多经验教训,特别是黏膜免疫的重要性,这些经验教训可以直接应用于流感保护相关因素。

相似文献

1
Meeting Report From "Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID-19 Pandemic".会议报告:“下一代流感疫苗的保护相关因素:从 COVID-19 大流行中吸取的经验教训”。
Influenza Other Respir Viruses. 2024 Oct;18(10):e13314. doi: 10.1111/irv.13314.
2
Influenza Virus and SARS-CoV-2 Vaccines.流感病毒和 SARS-CoV-2 疫苗。
J Immunol. 2021 Jun 1;206(11):2509-2520. doi: 10.4049/jimmunol.2001287. Epub 2021 May 21.
3
Developing Correlates of Protection for Vaccines Is Needed More than Ever-Influenza, COVID-19 and RSV Infection.开发疫苗保护相关物比以往任何时候都更加重要——流感、COVID-19 和 RSV 感染。
Viruses. 2024 Oct 25;16(11):1671. doi: 10.3390/v16111671.
4
Meeting report and review: Immunological assays and correlates of protection for next-generation influenza vaccines.会议报告和综述:下一代流感疫苗的免疫测定和保护相关性。
Influenza Other Respir Viruses. 2020 Mar;14(2):237-243. doi: 10.1111/irv.12706. Epub 2019 Dec 13.
5
Lessons Relearned? H1N1, COVID-19, and Vaccination Planning.吸取的教训?甲型H1N1流感、新冠疫情与疫苗接种规划。
J Public Health Manag Pract. 2021 Jan/Feb;27 Suppl 1, COVID-19 and Public Health: Looking Back, Moving Forward:S106-S110. doi: 10.1097/PHH.0000000000001289.
6
A decavalent composite mRNA vaccine against both influenza and COVID-19.一种针对流感和 COVID-19 的十价复合 mRNA 疫苗。
mBio. 2024 Sep 11;15(9):e0066824. doi: 10.1128/mbio.00668-24. Epub 2024 Aug 6.
7
Unravelling influenza correlates of protection: lessons from human A/H1N1 Challenge.解析流感保护相关性:来自人类 A/H1N1 挑战的经验教训。
mBio. 2024 May 8;15(5):e0006424. doi: 10.1128/mbio.00064-24. Epub 2024 Mar 28.
8
A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice.基于病毒粒子的联合疫苗可预防小鼠流感和 SARS-CoV-2 疾病。
J Virol. 2022 Aug 10;96(15):e0068922. doi: 10.1128/jvi.00689-22. Epub 2022 Jul 12.
9
[Vaccinations in pulmonary diseases - part 1: Covid and influenza].[肺部疾病中的疫苗接种 - 第1部分:新冠与流感]
Dtsch Med Wochenschr. 2024 Aug;149(17):1045-1049. doi: 10.1055/a-2115-0404. Epub 2024 Aug 15.
10
Host immune responses to influenza infection and vaccines: Lessons learned for all viral pandemic challenges.宿主对流感感染和疫苗的免疫反应:应对所有病毒性大流行挑战的经验教训。
Ann Allergy Asthma Immunol. 2020 Jul;125(1):2-3. doi: 10.1016/j.anai.2020.05.008.

引用本文的文献

1
Advancing influenza vaccines: A review of next-generation candidates and their potential for global health impact.推进流感疫苗:下一代候选疫苗及其对全球健康影响潜力的综述。
Vaccine. 2024 Dec 2;42(26):126408. doi: 10.1016/j.vaccine.2024.126408. Epub 2024 Oct 5.

本文引用的文献

1
Mucosal antibody responses to SARS-CoV-2 booster vaccination and breakthrough infection.黏膜抗体对 SARS-CoV-2 加强针接种和突破感染的反应。
mBio. 2023 Dec 19;14(6):e0228023. doi: 10.1128/mbio.02280-23. Epub 2023 Dec 1.
2
Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine.早期黏膜事件促进活减毒流感疫苗产生独特的黏膜和系统抗体应答。
Nat Commun. 2023 Dec 5;14(1):8053. doi: 10.1038/s41467-023-43842-7.
3
Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses.鉴定针对甲型流感病毒 M1 和 NP 的非中和性人源单克隆抗体。
J Virol. 2023 Nov 30;97(11):e0164622. doi: 10.1128/jvi.01646-22. Epub 2023 Nov 2.
4
Antibodies elicited in humans upon chimeric hemagglutinin-based influenza virus vaccination confer FcγR-dependent protection in vivo.基于嵌合血凝素的流感病毒疫苗接种在人体内诱导的抗体赋予 FcγR 依赖性的体内保护作用。
Proc Natl Acad Sci U S A. 2023 Oct 31;120(44):e2314905120. doi: 10.1073/pnas.2314905120. Epub 2023 Oct 23.
5
Utility of nasal swabs for assessing mucosal immune responses towards SARS-CoV-2.鼻拭子在评估针对 SARS-CoV-2 的黏膜免疫反应中的效用。
Sci Rep. 2023 Oct 19;13(1):17820. doi: 10.1038/s41598-023-44989-5.
6
Baseline innate and T cell populations are correlates of protection against symptomatic influenza virus infection independent of serology.基线先天和 T 细胞群体是与抗症状性流感病毒感染相关的保护因素,与血清学无关。
Nat Immunol. 2023 Sep;24(9):1511-1526. doi: 10.1038/s41590-023-01590-2. Epub 2023 Aug 17.
7
The role of vaccines in the COVID-19 pandemic: what have we learned?疫苗在 COVID-19 大流行中的作用:我们学到了什么?
Semin Immunopathol. 2024 Jan;45(4-6):451-468. doi: 10.1007/s00281-023-00996-2. Epub 2023 Jul 12.
8
Vaccine-induced correlate of protection against fatal COVID-19 in older and frail adults during waves of neutralization-resistant variants of concern: an observational study.在出现中和抗性关注变异株期间,老年和体弱成年人中疫苗诱导的针对致命性新冠病毒病的保护相关因素:一项观察性研究
Lancet Reg Health Eur. 2023 May 6;30:100646. doi: 10.1016/j.lanepe.2023.100646.
9
Haemagglutination inhibition and virus microneutralisation serology assays: use of harmonised protocols and biological standards in seasonal influenza serology testing and their impact on inter-laboratory variation and assay correlation: A FLUCOP collaborative study.血凝抑制和病毒微量中和血清学检测:在季节性流感血清学检测中使用协调一致的方案和生物标准及其对实验室间变异和检测相关性的影响:FLUCOP 合作研究。
Front Immunol. 2023 Apr 18;14:1155552. doi: 10.3389/fimmu.2023.1155552. eCollection 2023.
10
Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis.预测疫苗对 COVID-19 重症的长期有效性和对变异株的有效性:一项荟萃分析。
Nat Commun. 2023 Mar 24;14(1):1633. doi: 10.1038/s41467-023-37176-7.